| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ceb3b5e59a6335b315a8d20d5231b3aa |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-20033
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2496-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-20022
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-165 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56983
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5032
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate |
2021-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ef0739e63624cc72847ce49f2a030d1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_65090d59efd724820a940fcb96104af2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e172e828bed782f588131100b5eb6021
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57d537564f367206e4faf6005258ba98
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e4919398a5deefea11ccd28bed60d18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d49c19a528e412e6b29b921bfb4c758
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_edba172fb6c2133452721b09e487637f |
| publicationDate |
2022-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11479582-B2 |
| titleOfInvention |
Anti-SARS-CoV-2 fusion peptides |
| abstract |
Anti-SARS-CoV-2 fusion peptides are provided. The anti-SARS-CoV-2 fusion peptides include peptide sequences corresponding to the sequence of the SARS-CoV-2 fusion complex heptad repeat domain HR2 and having at least one artificial mutation. The anti-SARS-CoV-2 fusion peptides may be 39-mers, such as peptides #121 (SEQ ID NO: 2) and #125 (SEQ ID NO: 5). These peptides may competitively bind to SARS-CoV-2 and prevent either membrane mediated SARS-CoV-2 fusion, endocytosis-mediated viral entry, or both. The anti-SARS-CoV-2 fusion peptides may be administered to a subject in need thereof to inhibit or prevent SARS-CoV-2 cellular entry. |
| priorityDate |
2020-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |